logo
Share SHARE
FONT-SIZE Plus   Neg

Intrexon Files For IPO Of Up To $125 Mln

Biotechnology company Intrexon Corp. has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $125 million in an initial public offering of common stock. The company did not specify the number of shares to be sold and the price range for the proposed offering.

The Germantown, Maryland based company plans to list on the New York Stock Exchange under the ticker symbol XON.

The company said in a preliminary prospectus that it plans to use the proceeds to fund continued investment in research and development platforms and its business development efforts.

Intrexon is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems

Intrexon, which was founded in 1998, is now controlled by Randal Kirk, who has been the chief executive of the company since 2005.

J.P. Morgan and Barclays are the joint bookrunners on the deal.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
UK-based oil giant BP Plc. and French peer Total SA Tuesday reported lower profit for the first quarter, as oil prices declined sharply from the previous year. However, results reflected stronger overall refining environment. Hartford Financial reported a decline in first-quarter profit, despite growth in premiums, due mainly to the absence of gains recorded last year. Apple Inc. said Monday after the markets closed that its second quarter profit rose 33% from last year, driven by strong sales of iPhone and Mac as well as all-time record performance of the App Store. The company's quarterly earnings per share also breezed past Wall Street expectations as did its quarterly sales.
comments powered by Disqus
Follow RTT